EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diagnostic potential of genomic blood biomarkers of pulmonary fibrosis in a prospective cohort

Daniel He iD, Casey P Shannon iD, Jeremy A Hirota, Kjetil Ask, Christopher J Ryerson, Scott J Tebbutt iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0314876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Daniel He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Biomarkers, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibrotic interstitial lung diseases (ILDs) result from excessive deposition of extracellular matrix (ECM) proteins in the lung, causing irreversible damage to the lung architecture. Clinical management of ILDs differs depending on the diagnosis, but differentiation between subtypes can be difficult and better clinical biomarkers are needed. In this study, we use a 166-gene NanoString assay to investigate whether there are ILD subtype-specific transcripts in whole blood. We identified one transcript, killer cell lectin like receptor 1 ( KLRF1 ), as differentially expressed between idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated ILD (SSc-ILD), and identified two transcripts ( VCAN , LTK ) associated with IPF expression against other ILD subtypes. These findings were validated by examining their expression in ILD lung, with KLRF1 expression significantly higher in SSc-ILD compared to IPF and hypersensitivity pneumonitis (HP) samples. Taken together, this pilot study provides support for the use of the peripheral transcriptome in identifying diagnostic biomarkers of ILD with biological relevance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersIdiopathic Pulmonary FibrosisHumansMaleFemaleProspective StudiesMiddle AgedLung Diseases, InterstitialScleroderma, SystemicAgedAlveolitis, Extrinsic AllergicTranscriptomePilot ProjectsLectins, C-TypePulmonary FibrosisGenomics

Substanzen

BiomarkersLectins, C-Type

Autor:innen und Institutionen

  • Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada.
  • Prevention of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada.
  • Providence Health Care Research Institute, Providence Research, Vancouver, BC, Canada.
  • Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Department of Medicine, Firestone Institute for Respiratory Health-Division of Respirology, McMaster University, Hamilton, ON, Canada.

ORCID-Profile: Daniel He, Casey P Shannon, Scott J Tebbutt

Zitieren

APA

He, D., Shannon, C. P., Hirota, J. A., Ask, K., Ryerson, C. J., & Tebbutt, S. J. (2024). Diagnostic potential of genomic blood biomarkers of pulmonary fibrosis in a prospective cohort. PLOS ONE. https://doi.org/10.1371/journal.pone.0314876

Vancouver

He D, Shannon CP, Hirota JA, Ask K, Ryerson CJ, Tebbutt SJ. Diagnostic potential of genomic blood biomarkers of pulmonary fibrosis in a prospective cohort. PLOS ONE. 2024. doi:10.1371/journal.pone.0314876

BibTeX
@article{He2024,
  author = {He, Daniel and Shannon, Casey P and Hirota, Jeremy A and Ask, Kjetil and Ryerson, Christopher J and Tebbutt, Scott J},
  title = {Diagnostic potential of genomic blood biomarkers of pulmonary fibrosis in a prospective cohort},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0314876}
}
Kostenlos starten →